Production (Stage)
Turnstone Biologics Corp.
TSBX
$0.3329
-$0.0065-1.92%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 24.16M | 24.75M | 27.32M | 27.07M | 26.93M |
| Gross Profit | -24.16M | -24.75M | -27.32M | -27.07M | -26.93M |
| SG&A Expenses | 16.30M | 16.39M | 17.57M | 18.38M | 18.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.84M | 73.37M | 77.11M | 77.68M | 77.47M |
| Operating Income | -61.84M | -73.37M | -77.11M | -77.68M | -77.47M |
| Income Before Tax | -62.99M | -70.80M | -75.38M | -74.88M | -75.09M |
| Income Tax Expenses | 23.00K | 37.00K | -963.00K | -180.00K | -188.00K |
| Earnings from Continuing Operations | -63.01 | -70.84 | -74.42 | -74.70 | -74.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.01M | -70.84M | -74.42M | -74.70M | -74.90M |
| EBIT | -61.84M | -73.37M | -77.11M | -77.68M | -77.47M |
| EBITDA | -60.21M | -71.53M | -74.96M | -75.31M | -74.87M |
| EPS Basic | -2.73 | -3.08 | -3.23 | -3.49 | -10.12 |
| Normalized Basic EPS | -1.73 | -1.94 | -2.00 | -2.14 | -6.28 |
| EPS Diluted | -2.73 | -3.08 | -3.23 | -3.49 | -10.12 |
| Normalized Diluted EPS | -1.73 | -1.94 | -2.00 | -2.14 | -6.28 |
| Average Basic Shares Outstanding | 92.27M | 92.15M | 92.02M | 86.38M | 66.19M |
| Average Diluted Shares Outstanding | 92.27M | 92.15M | 92.02M | 86.38M | 66.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |